Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
An open single arm clinical study of combination of CFR64 T and anti-CD20 monoclonal antibodies for relapsed and refractory B-cell lymphoma
/ Not yet recruiting临床1期IIT Phase I clinical trial of CAR-T cell therapy targeting glycoprotein after failed first-line treatment of recurrent and metastatic nasopharyngeal carcinoma
100 项与 广东昭泰细胞生物科技有限公司 相关的临床结果
0 项与 广东昭泰细胞生物科技有限公司 相关的专利(医药)
100 项与 广东昭泰细胞生物科技有限公司 相关的药物交易
100 项与 广东昭泰细胞生物科技有限公司 相关的转化医学